Amicus Therapeutics : ESG Report

2024

Environmental,

Social, and

Governance

Report

IN THE FIGHT TO REMAIN AT THE FOREFRONT OF THERAPIES FOR RARE AND ORPHAN DISEASES™

Table of Contents

Overview

1. Message from the President & CEO
2. About Amicus
3. Amicus Aspirations & Achievements
4. ESG Program
5. Our ESG Initiatives & UN Sustainable Development Goals

Environmental Stewardship

1. Environmental Stewardship & Corporate Responsibility
2. Sustainability within Supply
3. Strengthening our Commitment to ESG through our Partnerships

Company Overview	Environmental Stewardship

Employees

1. Our Responsible Business
2. Talent Pipeline Development Strategy
3. Leadership Development and Learning Programs
4. Career Development Plans
5. Employee Recruitment, Engagement, and Retention

1. Employee Wellness
2. Human Capital
3. Diversity, Equity, and Inclusion
4. Employee Resource Groups
5. Corporate Social Responsibility
6. Employee Involvement in the Community

Patients

Employees

Governance

Patients	Governance
12	Patient Advocacy	34	Ethical Business Practices and Marketing
36	Compliance Program
13	Patient Advocacy and Engagement
37	ESG Governance
14Pricing Promise and Commitment to Patients
38	Board of Directors
15	Access & Affordability
39	Enterprise Risk Management
17Safety of Clinical Trials
40	Data Security and Privacy
18	Product Quality
41	Cybersecuity

Amicus Therapeutics 2024 ESG Report

1

Company Overview

Environmental Stewardship

Patients

Employees

Governance

Message from our President & CEO

I am pleased to share with you our annual Environmental, Social, and Governance (ESG) report and the initiatives we see as critical to our long-term success and our impact as a global biotechnology company.

Everyday Amicus is driven by a shared sense of purpose and commitment to people around the world living with a rare disease. Our work is founded in the belief that every person living with a rare disease deserves access to effective treatments. We also recognize that our responsibility extends beyond just the world of biotechnology and development of new therapies. To that end, we embrace our responsibility as stewards of the environment, social progress, and governance practices that are aligned with the values of our stakeholders.

Our accomplishments in 2023 represent the dedication Amicus brings to the rare disease community as we continued our mission of transforming the lives of people living with rare diseases.

Our achievements last year were highlighted by:

• Increasing access to Galafold with over 2,400 people living with Fabry disease around the world
• Receiving regulatory approvals of our second commercial therapy, Pombiliti™ + Opfolda™, in the United States, European Union, and the United Kingdom
• Delivering on our commitment to achieve non-GAAP profitability in the fourth quarter of the year
• Supporting a mission-focused culture where employees can contribute to winning teams, feel included, supported, and heard.
• Furthering our culture of strong business ethics and sound corporate governance philosophies
• Continuing to integrate sustainability best practices in our operations while delivering strong business growth
• Supporting our communities through global charitable giving

These achievements were accomplished through the hard work and commitment of our almost 500 employees. Our teams have worked to fulfill our mission and bring our treatments to as many people as possible.

As we reflect on the past year's accomplishments and set our sights on the year ahead, I extend my heartfelt gratitude to our employees, partners, and stakeholders for their support and dedication. We believe that through our shared sense of purpose, as well as, our ESG initiatives, we can create a better future for people living with rare diseases, our communities, and the world.

Together, we will continue to drive positive change, create shared value, and build a more sustainable future.

Sincerely,

Bradley L. Campbell

President and Chief Executive Officer

Amicus Therapeutics 2024 ESG Report

2

Company Overview

Environmental Stewardship

Patients

Employees

Governance

About Us

We are a global, patient-dedicated biotechnology company focused on developing

and delivering high-quality medicines for people living with rare diseases.

Amicus, the Latin word for friend, signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way. This spirit of empathy, compassion, and tenacity permeates our culture and influences all aspects of our approach to advancing cutting-edge technologies.

Definition:/:ə'mēkəs (noun) Latin Friend

Amicus Therapeutics 2024 ESG Report

3

Company Overview	Environmental Stewardship

Amicus Aspirations & Achievements

Patients

Employees

Governance

Environmental Stewardship

• Minimize our carbon footprint
• Engage and inform employees around good sustainability practices
• Increase usage of energy efficient lighting, appliances, and materials in our corporate offices
• Developing sustainability objectives with our manufacturing and supply partners to reduce GHG emissions
• Working towards quantifying our CO2 emissions produced during the supply chain
• Continue to have excellent oversight of climate related risks by identifying and implementing metrics to support oversight

Amicus Therapeutics 2024 ESG Report

Social

• Remain at the forefront of therapies for rare and orphan diseases
• Deliver the highest quality therapies for people living with these diseases
• Invest in a pipeline of next-generation therapies for those living with rare diseases
• Continue to support the disease communities and their families
• Encourage access to medicines through responsible pricing, disease awareness, and supportive services
• Provide a corporate culture that drives performance and ultimately attracts, energizes, and retains critical talent

Governance

• Maintain and foster our culture of strong business ethics and integrity, and ensure open lines of communication to encourage employee compliance reporting
• Continue partnering with all employees and stakeholders to ensure transparency and proper training on policies, procedures, and best practices
• Robust risk oversight by senior leadership and the Board of Directors

2023 Achievement Highlights

• Two approved therapies for the treatment of rare diseases: Galafold® for Fabry disease and Pombiliti™ + Opfolda™ for late-onset Pompe disease
• 2,600+ individuals treated through commercial, clinical, and expanded access programs
• 40+ countries with regulatory approval
• Received three prestigious awards for Pombiliti + Opfolda for our innovation and contributions towards improving the quality of healthcare and patient outcomes:
• • WORLDSymposium™ 2024 New Treatment Award
  • BioNJ 2023 Innovator Award
  • Life Sciences PA 2023 Patient Impact Award

4

Company Overview

ESG Program

Our dedication to patients goes hand in hand with our commitment to our environmental, social, and governance (ESG) program. Building strong ESG practices and oversight into our scientific and business activities creates a culture of integrity at every level of the organization, while safely and effectively delivering on our founding beliefs - be at the forefront of therapies for rare and orphan diseases, create long-term value for our stakeholders, and foster teamwork and respect for individual contributions.

Our foundational ESG initiatives are consistent with those identified by the Sustainability Accounting Standards Board (SASB) for the biotechnology and pharmaceuticals sector, and serve as a broad guide for our report content. We have also aligned our personal ESG practices and aspirations with several of the Sustainable Development Goals adopted by the United Nations in 2015. These goals provide a shared blueprint and call to action for all countries to foster initiatives that promote peace, prosperity, and a sustainable future for people and the planet. Additionally, in an effort to increase our awareness of our environmental impact, we have engaged with CDP, the gold standard in environmental reporting, for greater transparency into our environmental disclosures, as well as those within our supply and value chains.

The development and delivery of critical therapies for patients, clinical and regulatory compliance, employee engagement, and responsibility to our investors are underscored by our commitment to sustainable organizational development and growth. It is our belief that a sound governance structure, coupled with a socially and environmentally responsible mindset, provides the foundation for collective decision making and accountability across all facets of Amicus. Evolving our ESG program and its initiatives is a key goal for Amicus, and we look forward to reporting additional data and metrics relative to our ongoing progress on an annual basis.

Environmental Stewardship

Patients

Employees

Governance

Amicus Therapeutics 2024 ESG Report

5

Company Overview

Environmental Stewardship

Patients

Employees

Governance

Our ESG Initiatives &

UN Sustainable Development Goals

Environmental Stewardship

Responsible Consumption and Production

Amicus strives to integrate environmentally-conscious business practices and sustainability efforts into the day-to-day and long-term business to promote an environmentally-conscious corporate culture.

Human Capital

Good Health and Well-Being

Amicus is committed to ensuring the health and well-being of our global employees and people living with devastating rare diseases who can benefit from our therapies through global commercial, clinical and expanded access programs.

Governance

Peace, Justice, and Strong Institutions

Amicus is founded on core principles of integrity, accountability, and transparency, and governs with a set of business ethics that promote a culture of compliance that is supportive of equal opportunity and representation.

Quality Education

Amicus adopts career development initiatives

and provides our employees the tools and resources to grow personally and professionally to ensure

we can meaningfully engage with the global rare disease community.

		Gender Equality
		Amicus is dedicated to fostering an inclusive culture
		and works diligently to ensure equal participation for all
		in critical decision making, and the same opportunities
		for upward mobility.
Amicus Therapeutics 2024 ESG Report	6

Company Overview

Environmental Stewardship

Patients

Employees

Governance

Environmental Stewardship

Our eco-friendlydecision-making has identified economic efficiencies while continuing to bolster our standing as a good corporate citizen.

In this Section

Commitment and Objectives

Sustainability within Supply

Strengthening our Commitment to ESG through our Partnerships

UN Sustainable Development Goals

Amicus Therapeutics 2024 ESG Report

7

Company Overview		Environmental Stewardship	Patients	Employees	Governance

Environmental

Stewardship

& Corporate

Responsibility

We are committed to producing transformative medicines for patients while practicing environmental responsibility and adhering to sustainability best practices in our operations.

Reducing our Footprint

As a biotechnology company, our environmental footprint is relatively small in comparison to many other industries, yet we strive to minimize our footprint as much as possible. At Amicus, we recognize the severity of environmental impact and the need to continuously identify and assess areas of risks. As a result, we are working towards implementing robust sustainability objectives into our operations and with our manufacturing and supply partners to achieve a reduction in greenhouse gas (GHG) emissions.

2023 Sustainability Program

Objectives Achieved

• Continued to capture risk and opportunities in our partners' sustainability programs
• Implemented contractual obligations with suppliers to maintain good sustainability practices through their own ESG programs and review those programs as a standing agenda item in formal business reviews​
• Engaged employees around good sustainability practices through the GREEN employee resource group (ERG) to further educate on how Amicus and individuals can reduce our carbon footprint
• Greater efforts towards reducing our carbon footprint through a reduction in our facilities, increased hybrid working, and occupying office space that is commutable by walking, mass transit, or shared rides​
• Continued efforts towards gaining a better understanding of both Amicus' and our partners' GHG emissions and developing reduction targets to achieve our aspirational goal of carbon neutrality

0%

Amicus does not own any manufacturing facilities resulting in 0% Scope 1 and 2 GHG emissions

Engaging Employees in Sustainability

At Amicus, we recognize the importance of our employees' passion in fulfilling our sustainability commitments.

In 2024, we plan to offer new opportunities for our employees to engage with sustainability both inside and outside of work. We value our employees' input and will continue to listen to their suggestions and share updates on our sustainability efforts via company events and environment-related volunteering.

In April 2023, Amicus celebrated Earth Day globally in our Princeton, Philadelphia (USA), and Marlow (UK) offices. We handed out seed packets and hosted a "Plant a Seed for Good" event for employees to promote native wildlife and learn about the GREEN ERG's volunteering and giving opportunities.

Throughout 2023 Amicus held additional events for employees to learn more about community-led initiatives on sustainability such as, "Transition Town Marlow," "Emergency Relief Association," and "Operation Crop Drop."

Amicus Therapeutics 2024 ESG Report

8

Company Overview

Sustainability within Supply

Amicus Supply Partners Committed to Improving Green Credentials

At Amicus, sustainability means creating lasting social, environmental, and economic value by addressing the needs of the company's wide-ranging stakeholder base, including our manufacturing and distribution partners. Our mission is to drive sustainability with our partners, by incorporating environmental and sustainability principles into our commercial relationships. In order to do this, we want to ensure that we are aligned in our approach and establish the right priorities to help drive change.

Environmental Oversight and

Risk Assessment of Our Supply Partners

Our understanding of our suppliers' progress in implementing their own ESG programs continues to grow. We issued our annual survey to our suppliers and in all cases, it is evident that their programs continue to mature. We have now joined with CDP (a global platform for disclosing environmental information), to engage directly with our partners and consolidate environmental information across our entire supply chain. Working closely with our suppliers, we intend to utilize this information to bolster our own sustainability program and create a basis for direct action to improve our sustainability.

Environmental Stewardship

Patients

Employees

Governance

Amicus Therapeutics 2024 ESG Report

9